Table 1 Demographic, clinical features and outcomes of children with GMPP and SMPP

Demographics

Age (years)

6 (4, 8)

6 (3, 8)

0.213

Gender (male/female)

86 (42%)

107 (51%)

0.066

Clinical features

Underlying disease

8 (3.9%)

29 (13.7%)

<0.001

Disease day before admission

5.5 (3, 7)

7 (5, 10)

<0.001

Febrile day before admission

2 (2, 3)

6 (2, 8)

<0.001

Extrapulmonary complications

Adenoid hypertrophy

4 (1.9%)

1 (0.5%)

0.211

Acute otitis media

4 (1.9%)

5 (2.4%)

1.000

Rhinosinusitis

10 (4.9%)

7 (3.3%)

0.428

Cardiovascular system involvement

6 (2.9%)

16 (7.6%)

0.033

Neurologic involvement

0 (0%)

5 (2.4%)

0.061

Gastrointestinal involvement

12 (5.8%)

40 (19.0%)

<0.001

Treatment and outcomes

Antibiotic use^a

70 (34%)

168 (79.6%)

<0.001

Methylprednisolone sodium succinate

90 (43.7%)

173 (82%)

<0.001

Intravenous immunoglobulin

0 (0%)

21 (10%)

<0.001

Anticoagulation treatment

3 (1.5%)

36 (17.1%)

<0.001

Mechanical ventilation use

0 (0%)

25 (12%)

<0.001

Mechanical ventilation days

0

3 (2, 5)

<0.001

Respiratory failure

0 (0%)

15 (7.1%)

<0.001

Hospital duration

6 (5,8)

8 (7,12)

0.007

Death

0 (0%)

1 (0.5%)

1.000